Postmenopausal women who consume one or more sugar sweetened beverage daily appear to have a significantly higher risk of developing liver cancer and chronic liver disease than women… read more.
Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for… read more.
A novel artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center researchers to successfully detect lung cancer in a 2021 study has now… read more.
New instrument could aid diagnosis by helping surgeons pinpoint the best place for a biopsy. Researchers have developed an optical biopsy system that can distinguish between cancerous and… read more.
Advanced liver cancer, or hepatocellular carcinoma (HCC), currently has limited treatment options and poor prognosis • A recent study introduces a new approach to treat advanced HCC by… read more.
First national analysis of external-beam radiation as bridging therapy finds fewer than 4% of patients prescribed this non-invasive option. People with liver cancer awaiting transplantation could benefit from… read more.
Merck Inc announced that the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib met… read more.
A drug used to treat cirrhosis of the liver may be an effective treatment for a form of Dementia and motorneuron disease, scientists have discovered. The research, led… read more.
Article written by Bruce Sylvester Investigators have validated a first-line combination therapy that significantly improves survival in patients with hepatocellular carcinoma, the most common liver cancer.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
